715 related articles for article (PubMed ID: 19563866)
1. Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand.
Balkan W; Martinez AF; Fernandez I; Rodriguez MA; Pang M; Troen BR
Gene; 2009 Oct; 446(2):90-8. PubMed ID: 19563866
[TBL] [Abstract][Full Text] [Related]
2. AP-1 stimulates the cathepsin K promoter in RAW 264.7 cells.
Pang M; Martinez AF; Fernandez I; Balkan W; Troen BR
Gene; 2007 Nov; 403(1-2):151-8. PubMed ID: 17897792
[TBL] [Abstract][Full Text] [Related]
3. RANK ligand and interferon gamma differentially regulate cathepsin gene expression in pre-osteoclastic cells.
Pang M; Martinez AF; Jacobs J; Balkan W; Troen BR
Biochem Biophys Res Commun; 2005 Mar; 328(3):756-63. PubMed ID: 15694411
[TBL] [Abstract][Full Text] [Related]
4. High extracellular calcium-induced NFATc3 regulates the expression of receptor activator of NF-κB ligand in osteoblasts.
Lee HL; Bae OY; Baek KH; Kwon A; Hwang HR; Qadir AS; Park HJ; Woo KM; Ryoo HM; Baek JH
Bone; 2011 Aug; 49(2):242-9. PubMed ID: 21514407
[TBL] [Abstract][Full Text] [Related]
5. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.
Iwai K; Koike M; Ohshima S; Miyatake K; Uchiyama Y; Saeki Y; Ishii M
J Bone Miner Res; 2007 Oct; 22(10):1612-20. PubMed ID: 17576169
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T
Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
[TBL] [Abstract][Full Text] [Related]
7. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation.
Sundaram K; Nishimura R; Senn J; Youssef RF; London SD; Reddy SV
Exp Cell Res; 2007 Jan; 313(1):168-78. PubMed ID: 17084841
[TBL] [Abstract][Full Text] [Related]
8. Activation of the beta myosin heavy chain promoter by MEF-2D, MyoD, p300, and the calcineurin/NFATc1 pathway.
Meissner JD; Umeda PK; Chang KC; Gros G; Scheibe RJ
J Cell Physiol; 2007 Apr; 211(1):138-48. PubMed ID: 17111365
[TBL] [Abstract][Full Text] [Related]
9. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
10. Induction of DC-STAMP by alternative activation and downstream signaling mechanisms.
Yagi M; Ninomiya K; Fujita N; Suzuki T; Iwasaki R; Morita K; Hosogane N; Matsuo K; Toyama Y; Suda T; Miyamoto T
J Bone Miner Res; 2007 Jul; 22(7):992-1001. PubMed ID: 17402846
[TBL] [Abstract][Full Text] [Related]
11. Aldehydic components of cinnamon bark extract suppresses RANKL-induced osteoclastogenesis through NFATc1 downregulation.
Tsuji-Naito K
Bioorg Med Chem; 2008 Oct; 16(20):9176-83. PubMed ID: 18823786
[TBL] [Abstract][Full Text] [Related]
12. MHC class II transactivator negatively regulates RANKL-mediated osteoclast differentiation by downregulating NFATc1 and OSCAR.
Kim JH; Kim K; Youn BU; Jin HM; Kim N
Cell Signal; 2010 Sep; 22(9):1341-9. PubMed ID: 20466061
[TBL] [Abstract][Full Text] [Related]
13. Regulation of osteoclast differentiation and function by the CaMK-CREB pathway.
Sato K; Suematsu A; Nakashima T; Takemoto-Kimura S; Aoki K; Morishita Y; Asahara H; Ohya K; Yamaguchi A; Takai T; Kodama T; Chatila TA; Bito H; Takayanagi H
Nat Med; 2006 Dec; 12(12):1410-6. PubMed ID: 17128269
[TBL] [Abstract][Full Text] [Related]
14. Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation.
Song I; Kim JH; Kim K; Jin HM; Youn BU; Kim N
FEBS Lett; 2009 Jul; 583(14):2435-40. PubMed ID: 19576893
[TBL] [Abstract][Full Text] [Related]
15. NFATc1 regulation of the human beta3 integrin promoter in osteoclast differentiation.
Crotti TN; Flannery M; Walsh NC; Fleming JD; Goldring SR; McHugh KP
Gene; 2006 May; 372():92-102. PubMed ID: 16513293
[TBL] [Abstract][Full Text] [Related]
16. AP-1 and Mitf interact with NFATc1 to stimulate cathepsin K promoter activity in osteoclast precursors.
Pang M; Rodríguez-Gonzalez M; Hernandez M; Recinos CC; Seldeen KL; Troen BR
J Cell Biochem; 2019 Aug; 120(8):12382-12392. PubMed ID: 30816596
[TBL] [Abstract][Full Text] [Related]
17. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
[TBL] [Abstract][Full Text] [Related]
19. NFATc1 activates the acetylcholinesterase promoter in rat muscle.
Cohen TV; Randall WR
J Neurochem; 2004 Sep; 90(5):1059-67. PubMed ID: 15312161
[TBL] [Abstract][Full Text] [Related]
20. RANKL-induced schlafen2 is a positive regulator of osteoclastogenesis.
Lee NK; Choi HK; Yoo HJ; Shin J; Lee SY
Cell Signal; 2008 Dec; 20(12):2302-8. PubMed ID: 18796328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
